Inipharm, a Seattle and San Diego-based biopharmaceutical company focused on discovering and developing therapies for severe liver diseases, closed a $35m Series A financing round.
Backers included 5AM Ventures and Wu Capital which joined existing investors Frazier Healthcare Partners and Jubilant Biosys Limited. The company also announced that Brian Daniels, M.D., partner at 5AM Ventures, and Hannah Chang, M.D., Ph.D., managing director at Wu Capital, have joined Inipharm’s board of directors.
Founded in 2018, Inipharm is focused on discovering and developing therapies for liver and related diseases, with its initial program focused on those associated with the genetically defined target HSD17B13.
The Series A funding will support the advancement of Inipharm’s lead program through IND filing and into clinical trials.
Led by Brian Farmer, co-founder and chief executive officer, Heather Hsu, Ph.D., CSO, Vince Florio, Ph.D., and Joshua Odingo, Ph.D., who lead pharmacology and chemistry, Inipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases. Its program is focused on targeting the activity of the HSD17B13 gene.
Also serving on the board of directors are Michael Gallatin Ph.D., co-founder of Inipharm and chair of the company’s scientific advisory board, and Bob Baltera, CEO of Cirius Therapeutics.
FinSMEs
11/11/2020